CN105770227A - Traditional Chinese medicine compound for treating dysmenorrhea and preparation method thereof - Google Patents
Traditional Chinese medicine compound for treating dysmenorrhea and preparation method thereof Download PDFInfo
- Publication number
- CN105770227A CN105770227A CN201610275734.XA CN201610275734A CN105770227A CN 105770227 A CN105770227 A CN 105770227A CN 201610275734 A CN201610275734 A CN 201610275734A CN 105770227 A CN105770227 A CN 105770227A
- Authority
- CN
- China
- Prior art keywords
- parts
- dysmenorrhea
- crude drug
- chinese medicine
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound for treating dysmenorrhea and a preparation method thereof. The traditional Chinese medicine compound is prepared from crude medicinal herbs including, by weight, 55-65 parts of Fructus ligustri lucidi, 35-45 parts of Cortex moutan, 20-30 parts of Rosa sinensis, 15-25 parts of cassia twig, 20-30 parts of pummelo peel, 35-45 parts of Cortex eucommia, 5-15 parts of Rhizoma curculiginis and 40-60 parts of Flos albizae and hawthorn, wherein a weight part ratio of Flos albizae to hawthorn is 3-5:1. The traditional Chinese medicine compound can remarkably inhibit dysmenorrhea of mice and can be developed to treat dysmenorrhea. The action of the traditional Chinese medicine compound may have something to do with the weight part ratio of Flos albizae to hawthorn.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine compound treating dysmenorrhea and preparation method thereof.
Background technology
Dysmenorrhea is one of modal gynecological symptom, before and after referring to pass through or menstrual phase lower abdominal pain, falling inflation occur, with the soreness of waist or other are uncomfortable, serious symptom affects quality of life.Dysmenorrhea is divided into primary dysmenorrhea and Secondary cases two class, and primary dysmenorrhea refers to genitals's dysmenorrhea without organic disease, accounts for dysmenorrhea more than 90%；Secondary dysmenorrhea refers to the dysmenorrhea caused by pelvic cavity organic disease.
Dysmenorrhea is common symptom in women, and after pre-marital dysmenorrhea is particularly given birth to after growing up after marriage, dysmenorrhea can disappear naturally, it may not be necessary to treatment.Except individual cases.But the pain time of dysmenorrhea should be treated up to 3 days persons.The treatment of primary dysmenorrhea, mainly symptomatic treatment, with pain relieving, calmness is main, all adopts Comprehensive Treatment to include spirit in recent years and dredges, Chinese medicine, Western medicine and acupuncture and moxibustion therapy.
Summary of the invention
The first object of the present invention is in that to provide a kind of Chinese medicine compound, is used for treating dysmenorrhea；
The second object of the present invention is in that to provide a kind of active ingredient of Chinese herbs extractum utilizing above-mentioned Chinese medicine compound to prepare；
The third object of the present invention is in that to provide a kind of compound Chinese medicinal preparation treating dysmenorrhea, containing above-mentioned active ingredient of Chinese herbs extractum and pharmaceutically acceptable adjuvant.
The above-mentioned purpose of the present invention is achieved by the techniques below scheme:
A kind of Chinese medicine compound treating dysmenorrhea, is prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 55～65 parts；Cortex Moutan, 35～45 parts；Flos Rosae Chinensis, 20～30 parts；Ramulus Cinnamomi, 15～25 parts；Exocarpium Citri Grandis, 20～30 parts；The Cortex Eucommiae, 35～45 parts；Rhizoma Curculiginis, 5～15 parts；Flos Albiziae and Fructus Crataegi totally 40～60 parts, the two weight ratio is 3～5:1.
Further, the Chinese medicine compound of described treatment dysmenorrhea is prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 4:1.
Further, the Chinese medicine compound of described treatment dysmenorrhea is prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 55 parts；Cortex Moutan, 35 parts；Flos Rosae Chinensis, 20 parts；Ramulus Cinnamomi, 15 parts；Exocarpium Citri Grandis, 20 parts；The Cortex Eucommiae, 35 parts；Rhizoma Curculiginis, 5 parts；Flos Albiziae and Fructus Crataegi totally 40 parts, the two weight ratio is 3:1.
Further, the Chinese medicine compound of described treatment dysmenorrhea is prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 65 parts；Cortex Moutan, 45 parts；Flos Rosae Chinensis, 30 parts；Ramulus Cinnamomi, 25 parts；Exocarpium Citri Grandis, 30 parts；The Cortex Eucommiae, 45 parts；Rhizoma Curculiginis, 15 parts；Flos Albiziae and Fructus Crataegi totally 60 parts, the two weight ratio is 5:1.
A kind of active ingredient of Chinese herbs extractum treating dysmenorrhea, is prepared from by above-mentioned Chinese medicine compound, comprises the steps: that the crude drug taking formula ratio extracts 2～3 times with 70～90% alcohol heat reflux, and united extraction liquid, concentration, spray drying obtains extract powder.
Further, the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, united extraction liquid.
Further, being concentrated into density is 1.15～1.35.
Further, every gram of extract powder is equivalent to crude drug 3～5g.
A kind of compound Chinese medicinal preparation treating dysmenorrhea, containing above-mentioned active ingredient of Chinese herbs extractum and pharmaceutically acceptable adjuvant, conventionally prepares into preparation.
Further, described preparation includes granule, tablet, capsule, injection, oral liquid.
Advantages of the present invention:
1, Chinese medicine compound provided by the invention proves to treat dysmenorrhea through pharmacological evaluation；
2, active ingredient of Chinese herbs extractum provided by the invention extracted by Chinese medicine compound provided by the invention, concentration be prepared from, it is possible to significantly treat dysmenorrhea；
3, compound Chinese medicinal preparation provided by the invention contains active ingredient of Chinese herbs extractum provided by the invention and pharmaceutically acceptable adjuvant carrier, it is possible to be used for treating dysmenorrhea.
Detailed description of the invention
Further illustrate the essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although the present invention being explained in detail with reference to preferred embodiment, it will be understood by those within the art that, it is possible to technical scheme is modified or equivalent replacement, without deviating from the spirit and scope of technical solution of the present invention.Crude drug Ji Yuan and the 2015 edition Chinese Pharmacopoeia related in the present invention is consistent.
Embodiment 1: the preparation of active component extractum
Crude drug formula:
Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 4:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.25, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 4g.
Embodiment 2: the preparation of active component extractum
Crude drug formula:
Fructus Ligustri Lucidi, 55 parts；Cortex Moutan, 35 parts；Flos Rosae Chinensis, 20 parts；Ramulus Cinnamomi, 15 parts；Exocarpium Citri Grandis, 20 parts；The Cortex Eucommiae, 35 parts；Rhizoma Curculiginis, 5 parts；Flos Albiziae and Fructus Crataegi totally 40 parts, the two weight ratio is 3:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 70% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.15, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 3g.
Embodiment 3: the preparation of active component extractum
Crude drug formula:
Fructus Ligustri Lucidi, 65 parts；Cortex Moutan, 45 parts；Flos Rosae Chinensis, 30 parts；Ramulus Cinnamomi, 25 parts；Exocarpium Citri Grandis, 30 parts；The Cortex Eucommiae, 45 parts；Rhizoma Curculiginis, 15 parts；Flos Albiziae and Fructus Crataegi totally 60 parts, the two weight ratio is 5:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 90% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.35, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 5g.
Embodiment 4: the preparation of active component extractum
Crude drug formula:
Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 3:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.25, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 4g.
Embodiment 5: the preparation of active component extractum
Crude drug formula:
Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 5:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.25, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 4g.
Embodiment 6: the contrast of embodiment 1, Flos Albiziae and Fructus Crataegi weight ratio are 2:1
Crude drug formula:
Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 2:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.25, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 4g.
Embodiment 7: the contrast of embodiment 1, Flos Albiziae and Fructus Crataegi weight ratio are 6:1
Crude drug formula:
Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 6:1.
Preparation method: the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, and united extraction liquid, being concentrated into density is 1.25, and spray drying obtains extract powder, and every gram of extract powder is equivalent to crude drug 4g.
Embodiment 8: treatment dysmenorrhea effect
The present embodiment uses oxytocin and hot plate method to prepare dysmenorrhea mouse model respectively, observes the medicine impact on dysmenorrhea model in mice.
1, materials and methods
1.1 animals
C57BL/6 mice 132, female mice, 7～8 week old, body weight 18～22g, purchased from Institute of Experimental Animals, Chinese Academy of Medical Sciences.Animal feeding temperature (22 ± 1) DEG C, relative humidity 55%～65%, 12h periodicity of illumination aeration-drying environment in, adopt big mice maintain material 1022 raising.
1.2 reagent and sample
Active component extractum 1～7 is prepared respectively by embodiment 1～7 method.Tween 80 (chemicals company limited of traditional Chinese medicines group)；Synestrin tablets is purchased from Tianjin Li Sheng pharmaceutical factory product；Oxytocin injection is purchased from Ma'an Mountain of Anhui Province biochemical-pharmaceutical factory product；Ibuprofen ibuprofen modified release capsule is purchased from Sino-America Tianjin Shike Pharmaceutical Co., Ltd..
1.3 equipment
Pulverizer (Wuyi County stand erect Tools Co., ltd, QE-100g)；Disposable sterilized syringe (Yangzhou Great Wall medical apparatus and instruments factory)；Beaker, graduated cylinder, mortar etc..
1.4 writhing assay
Female mice is randomly divided into 10 groups, often group 12, respectively as do not model group (Normal group), modeling be not administered group (model control group), positive drug control group, active component extractum 1～7 group.Every day, after injection in the 6th day, water 12h was can't help in each treated animal fasting to mouse subcutaneous injection diethylstilbestrol 0.4ml/20g (except Normal group), continuous 5d.7th day gastric infusion 1 time, active component extractum 1～7 group is administered active component extractum 1～7 (160mg/kg) respectively；Positive drug control group gives ibuprofen 100mg/kg.1h lumbar injection oxytocin 0.2g/kg after administration, observes mice writhing number of times in 30min after injecting oxytocin.
1.5 hot-plates
The medicine impact on the mice threshold of pain: selecting weight is the mice of 18～22g, and measures its threshold of pain at RB-200 intelligence hot-plate instrument in advance.All lower than 5s or do not lick rear solid end or escapee in 30s, giving it up.By qualified for threshold of pain mice 90, it is randomly divided into 9 groups: respectively as Normal group, positive drug control group, active component extractum 1～7 group.Respectively organize gastric infusion: active component extractum 1～7 group is administered active component extractum 1～7 (160mg/kg) respectively, and positive drug control group gives ibuprofen 100mg/kg, and Normal group gives purified water.Successive administration 7d, (putting into from mice and start to occurring that mice licks metapedes due to thermostimulation, this period, hot plate temperature was set as (55.0 ± 0.5) DEG C as the threshold of pain to measure the threshold of pain with RB-200 intelligence hot-plate instrument after last administration 1h.Observe the medicine impact on the mice threshold of pain.
1.6 statistical methods
Experimental data mean ± standard deviation (x ± s) represents, application SPSS18.0 version statistical software carries out one factor analysis of variance and t inspection, statistically significant for difference with P < 0.05.
2, experimental result
The impact of the dysmenorrhea model mice pain that oxytocin is brought out by 2.1
After mice gives oxytocin 10min, it can be observed that mouse writhing number of times increases.Comparing with Normal group, there is dysmenorrhea in model control group mice, and showing as writhing number of times increases, writhing increased frequency (P < 0.01) in 30min；Comparing with model control group, active component extractum 1～5 group and positive drug control group writhing number of times substantially reduce (P < 0.01), and mice pain significantly improves；Comparing with model control group, 6,7 groups of writhing number of times of active component extractum are without notable change (P > 0.05).In Table 1.
2.2 impacts on hot plate method dysmenorrhea model mice
Comparing with Normal group, active component extractum 1～5 group and positive drug control group pain reaction time significantly extend (P < 0.01)；Comparing with Normal group, 6,7 groups of pain reaction of active component extractum are without notable change (P > 0.05).In Table 1.
The table 1 impact on dysmenorrhea model mouse writhing behavior and hot plate behavior
| Group | Writhing number of times/30min | The front threshold of pain (s) of medicine | The threshold of pain (s) after medicine |
| Normal group | 16 | 17.7±3.7 | / |
| Model control group | 36 | / | / |
| Positive drug control group | 15 | 17.5±3.4 | 48.9±17.3 |
| Active component extractum 1 group | 13 | 17.5±3.5 | 73.5±15.5 |
| Active component extractum 4 groups | 15 | 17.6±3.5 | 53.5±12.5 |
| Active component extractum 5 groups | 15 | 17.6±3.5 | 53.9±12.1 |
| Active component extractum 6 groups | 34 | 17.5±3.5 | 19.6±3.2 |
| Active component extractum 7 groups | 34 | 17.7±3.7 | 20.2±3.0 |
Active component extractum 2,3 and active component extractum 4,5 action effect are basically identical.
Above-mentioned test shows, Chinese medicine compound provided by the invention can significantly inhibit mice dysmenorrhea, it is possible to develop into the Chinese medicine compound for the treatment of dysmenorrhea.This effect of Chinese medicine compound of the present invention is likely to relevant with the weight ratio of crude drug Flos Albiziae and Fructus Crataegi.
Embodiment 9: the preparation of granule
First prepare active component extractum by embodiment 1 method, add excipient with excipient weight than the ratio for 1:12 in it, make granule.
Embodiment 10: the preparation of tablet
First prepare active component extractum by embodiment 1 method, add excipient, pelletizing press sheet with excipient weight than the ratio for 1:12 in it.
Embodiment 11: the preparation of injection
First preparing active component extractum by embodiment 1 method, inject routinely and use water, fine straining, injection is made in embedding sterilizing.
Embodiment 12: the preparation of oral liquid
First prepare active component extractum by embodiment 1 method, oral liquid method for making makes oral liquid routinely.
Embodiment 13: the preparation of capsule
First prepare active component extractum by embodiment 1 method, add excipient with excipient weight than the ratio for 1:12 in it, make capsule.
The effect of above-described embodiment indicates that the essentiality content of the present invention, but does not limit protection scope of the present invention with this.It will be understood by those within the art that, it is possible to technical scheme is modified or equivalent replacement, without deviating from essence and the protection domain of technical solution of the present invention.
Claims (10)
1. the Chinese medicine compound treating dysmenorrhea, it is characterised in that be prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 55～65 parts；Cortex Moutan, 35～45 parts；Flos Rosae Chinensis, 20～30 parts；Ramulus Cinnamomi, 15～25 parts；Exocarpium Citri Grandis, 20～30 parts；The Cortex Eucommiae, 35～45 parts；Rhizoma Curculiginis, 5～15 parts；Flos Albiziae and Fructus Crataegi totally 40～60 parts, the two weight ratio is 3～5:1.
2. the Chinese medicine compound for the treatment of dysmenorrhea according to claim 1, it is characterised in that be prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 60 parts；Cortex Moutan, 40 parts；Flos Rosae Chinensis, 25 parts；Ramulus Cinnamomi, 20 parts；Exocarpium Citri Grandis, 25 parts；The Cortex Eucommiae, 40 parts；Rhizoma Curculiginis, 10 parts；Flos Albiziae and Fructus Crataegi totally 50 parts, the two weight ratio is 4:1.
3. the Chinese medicine compound for the treatment of dysmenorrhea according to claim 1, it is characterised in that be prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 55 parts；Cortex Moutan, 35 parts；Flos Rosae Chinensis, 20 parts；Ramulus Cinnamomi, 15 parts；Exocarpium Citri Grandis, 20 parts；The Cortex Eucommiae, 35 parts；Rhizoma Curculiginis, 5 parts；Flos Albiziae and Fructus Crataegi totally 40 parts, the two weight ratio is 3:1.
4. the Chinese medicine compound for the treatment of dysmenorrhea according to claim 1, it is characterised in that be prepared from by the crude drug of following weight ratio: Fructus Ligustri Lucidi, 65 parts；Cortex Moutan, 45 parts；Flos Rosae Chinensis, 30 parts；Ramulus Cinnamomi, 25 parts；Exocarpium Citri Grandis, 30 parts；The Cortex Eucommiae, 45 parts；Rhizoma Curculiginis, 15 parts；Flos Albiziae and Fructus Crataegi totally 60 parts, the two weight ratio is 5:1.
5. treat an active ingredient of Chinese herbs extractum for dysmenorrhea, the Chinese medicine compound as described in as arbitrary in Claims 1 to 4 be prepared from, it is characterised in that, comprise the steps: that the crude drug taking formula ratio extracts 2～3 times with 70～90% alcohol heat reflux, united extraction liquid, concentration, spray drying obtains extract powder.
6. active ingredient of Chinese herbs extractum according to claim 5, it is characterised in that: the crude drug taking formula ratio extracts 2～3 times with 80% alcohol heat reflux, united extraction liquid.
7. active ingredient of Chinese herbs extractum according to claim 5, it is characterised in that: being concentrated into density is 1.15～1.35.
8. active ingredient of Chinese herbs extractum according to claim 5, it is characterised in that: every gram of extract powder is equivalent to crude drug 3～5g.
9. the compound Chinese medicinal preparation treating dysmenorrhea, it is characterised in that: containing, for example the arbitrary described active ingredient of Chinese herbs extractum of claim 5～8 and pharmaceutically acceptable adjuvant, conventionally prepare into preparation.
10. compound Chinese medicinal preparation according to claim 9, it is characterised in that: described preparation includes granule, tablet, capsule, injection, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610275734.XA CN105770227A (en) | 2016-04-29 | 2016-04-29 | Traditional Chinese medicine compound for treating dysmenorrhea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610275734.XA CN105770227A (en) | 2016-04-29 | 2016-04-29 | Traditional Chinese medicine compound for treating dysmenorrhea and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105770227A true CN105770227A (en) | 2016-07-20 |
Family
ID=56398996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610275734.XA Pending CN105770227A (en) | 2016-04-29 | 2016-04-29 | Traditional Chinese medicine compound for treating dysmenorrhea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105770227A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095610A (en) * | 1993-05-24 | 1994-11-30 | 潘世庆 | The pharmaceutical preparation Fubingkang of treatment, prevention gynecological diseases |
| CN101822762A (en) * | 2010-05-20 | 2010-09-08 | 南京中医药大学 | Chinese herbal compound effective composite for treating dysmenorrhea and preparation method and application thereof |
| CN105726533A (en) * | 2016-03-24 | 2016-07-06 | 庄立 | Pharmaceutical composition of antazoline hydrochloride and medical application thereof in treating dysmenorrhea |
-
2016
- 2016-04-29 CN CN201610275734.XA patent/CN105770227A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095610A (en) * | 1993-05-24 | 1994-11-30 | 潘世庆 | The pharmaceutical preparation Fubingkang of treatment, prevention gynecological diseases |
| CN101822762A (en) * | 2010-05-20 | 2010-09-08 | 南京中医药大学 | Chinese herbal compound effective composite for treating dysmenorrhea and preparation method and application thereof |
| CN105726533A (en) * | 2016-03-24 | 2016-07-06 | 庄立 | Pharmaceutical composition of antazoline hydrochloride and medical application thereof in treating dysmenorrhea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101385848B (en) | Medicine for treating bronchitis | |
| CN101933991B (en) | Analgesic and anti-inflammatory medicament and preparation method thereof | |
| CN104367765A (en) | Traditional Chinese medicinal composition for treating depression as well as preparation method and application thereof | |
| CN103751497A (en) | Medicament for treating mastitis and preparation method thereof | |
| CN101926865B (en) | Spina date seed depression-resolving and nerve-soothing composition and preparation method thereof | |
| CN103083500A (en) | Chinese medicinal composition treating toxoplasmosis | |
| CN104248722A (en) | Medicament for treating female hypersexuality | |
| CN103405719A (en) | Medicament for treatment of depression | |
| CN101301357A (en) | Use of schisandra chinensis extract in anti-depression medicament | |
| CN104027522A (en) | Traditional Chinese medicament for treating acute appendicitis | |
| CN104069454A (en) | Traditional Chinese medicine for treating epilepsy | |
| CN104306846A (en) | Traditional Chinese medicine for treating attention deficit hyperactivity disorder | |
| CN105770227A (en) | Traditional Chinese medicine compound for treating dysmenorrhea and preparation method thereof | |
| CN103893502A (en) | Traditional Chinese medicine for treating phlyctenular conjunctivitis | |
| CN104547683B (en) | A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN103341154A (en) | Compound veterinary injection for clearing heat and removing toxin | |
| CN106265927A (en) | A kind of pharmaceutical composition for treating rhinitis and nasosinusitis and allergic rhinitis | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN1899428B (en) | Chinese medicine preparation for treating pain and its preparing method | |
| CN1846721B (en) | Tranquilizing seven-leaf oral cavity disintegrated tablet and its preparation method | |
| Van Trung et al. | 9. Anxiolytic effect of the herbal remedy “Ky cuc dia hoang thang gia vi” in experimental animals | |
| CN104547786A (en) | Externally applied traditional Chinese medicine composite for treating hyperandrogenitic acne, and application | |
| CN102988941A (en) | Medicament for treating dysmenorrhea | |
| CN104740579A (en) | Premenstrual calming tablet and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160720 |
|
| RJ01 | Rejection of invention patent application after publication |